far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety. Spinomix’ products MagPhase™ and FibroTrap™ improve the accuracy and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse (e.g. blood, urine, swabs and food matrices).

Today many aspects of sample processing are still labour and time intensive. Therefore, there is a significant opportunity for Spinomix’s technologies to streamline the process. They are targeting double-digit growth markets such as nucleic acids extraction, believed to be worth $2 billion; cell separation growing to over $2.5 billion; food safety at over $2 billion; and molecular diagnostics for infectious diseases estimated at $2.7 billion.

Their current approach is to concentrate on product innovation and market validation. They have collaboration agreements in place and are conducting validation programs of their products with key market players in research and industry. Their goal is to develop these collaborations into strategic commercial partnerships to license their products.